Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Down 41.9% in October

Alterity Therapeutics Limited (NASDAQ:ATHE) was the target of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 3,600 shares, a drop of 41.9% from the October 15th total of 6,200 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 12,000 shares, the days-to-cover ratio is presently 0.3 days.

Alterity Therapeutics Stock Performance

ATHE traded down $0.07 during midday trading on Friday, reaching $1.11. The company’s stock had a trading volume of 13,112 shares, compared to its average volume of 44,340. The company has a fifty day simple moving average of $1.24 and a 200 day simple moving average of $1.58. Alterity Therapeutics has a twelve month low of $1.01 and a twelve month high of $5.41.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.